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In South Africa, there is an increasing population of those with both Human 
Immunodeficiency Virus (HIV) and one or more non-communicable diseases (NCDs).  This is 
thought to be due to a number of factors, including both the successful Antiretroviral 
Therapy (ART) programme (which has increased the life-expectancy of those with HIV) and 
the increasing prevalence of NCDs (due to an aging population, lifestyle changes and 
urbanisation).  This co-morbid population has been shown have poor health outcomes 
especially in terms of adherence (due to pill burden, multiple appointments etc).  There are 
currently very few models of integrated care for those with both HIV and NCDs, despite 
well-documented potential benefits of this approach for both the patient and the health 
system (in terms of efficiency).  One such model of care, the co-morbidity adherence clubs 
(for those with both HIV and hypertension and/or diabetes), was implemented in 2016 in 
South Africa and this study aims to compare the key outcomes of retention and viral 
suppression between these clubs and the established HIV-only adherence clubs.   
Part A is the study protocol which lays the foundation for the need for this research, and 
explains how the research will be conducted.  Part B forms the literature review which gives 
a summary of the existing literature and provides context for the dissertation.  Part C is the 
manuscript, presenting the analysis of the retrospective cohort study, and includes a 
discussion on the implications of key findings.    
The study sample comprised 602 HIV-positive adults (501 from the HIV-only club model and 
101 from the co-morbidity club model).  The overall female proportion was 70.3% and the 
median age was 38 years.  The results showed that there was no difference in the 
proportion of those retained (84.2% vs 85.6%, p=0.703) or the proportion who were virally 
suppressed (97% vs 97%, p=0.999) in the co-morbidity club compared to the HIV-only club.  
In multivariable logistic regression models, adjusted for age, sex and duration on ART, there 
was no significant difference in retention (adjusted odds ratio [aOR] 0.75 95% confidence 
interval [CI] 0.38, 1.47) or viral suppression (aOR 0.98 95% CI 0.23, 4.14) by club model.  The 
most common reason for loss of retention from the HIV-only club was non-attendance 
whereas for the co-morbidity club it was being sent back to clinic for high blood pressure.   
This study provides early evidence of comparable short-term patient outcomes between 
HIV-only and co-morbidity club models and provides reassurance that co-morbidity clubs 
can be implemented without affecting the outcomes of HIV care.  It also provides early 
promise that, whilst the differential reasons for loss of retention by club model merit further 
investigation, patients with HIV and hypertension and/or diabetes can safely be managed in 
co-morbidity clubs.  
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Part A: Protocol 
 
A Retrospective Cohort Study comparing Retention and Viral suppression between Co-




Human Immunodeficiency Virus (HIV) is now recognised by WHO as a chronic disease as it 
fits the description of a condition requiring ongoing management over years [1].  This is due 
to the introduction and subsequent scale-up of anti-retroviral therapy (ART) which has 
decreased mortality and increased life-expectancy, and has been aided by ambitious targets 
for ART uptake and adherence such as the UNAIDS 90-90-90 guidelines [2,3].  This vertical 
programme global public health success, however, has had the consequence of generating 
increasingly large numbers of people living with HIV (PLHIV).  These PLHIV are at risk of 
developing non-communicable diseases (diseases without an infective cause, often referred 
to as NCDs) due not only to their increasing age and decreasing mortality but also to the HIV 
infection itself and ART side-effects [4].  Reported prevalence of diabetes and hypertension 
in PLHIV in low-and-middle-income countries are estimated at 1.3-18% and 21.2% 
respectively, and this prevalence increases with age [5]. 
 
Whilst the increase in prevalence of NCDs is a global phenomenon, with 36 million deaths 
annually, low-income countries carry the highest burden of both morbidity and mortality.  In 
Africa alone, the number of people with diabetes was estimated at around 16 million in 
2017, and 80% of NCD deaths occur in low-income countries [6,7].   Sub-Saharan Africa, with 
its well-documented high burden of HIV, is thus experiencing a dual disease burden and a 
relatively new population of adults with co-existing chronic disease in the form of HIV and 
NCDs [8].  There is therefore a necessity to address the health needs of this population.  
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The scale-up of the ART programme has been largely successful and so there is a growing 
interest in harnessing this model to address the needs of this new population by integrating 
NCD care into the existing HIV health systems [9]. Such a horizontal programme approach is 
potentially more sustainable (in terms of resources and finances) as well as being more 
patient- and adherence-centred (through reduced appointment frequency) [8,10].  There are 
also shared characteristics between chronic HIV and NCDs in terms of progression over 
time, the importance of adherence and retention in services,  and the need for continuous 
follow-up and support [11]. 
 
Although WHO calls for integrated NCD programmes, there is little research evidence 
currently on the outcomes of such systems, with the few studies being descriptive or 
implementation-focussed [12,13].  However, some early evidence has been encouraging.  In 
a study of patients with both HIV and diabetes at an HIV clinic in the USA, the proportion of 
patients who met HbA1c goals was reported to be comparable (at 54%) to those people 
with diabetes without HIV, demonstrating that HIV infection need not be a barrier to the 
achievement of good glycaemic control [14].  This was further demonstrated in a 
retrospective record review in Kenya which found that NCD outcomes (blood pressure and 
HbA1c) were similar between HIV positive and HIV negative patients [15].  A prospective 
cohort study in Cambodia which looked at patients with HIV, hypertension or diabetes 
treated in newly implemented chronic disease clinics found reasonable retention outcomes 
at two years, being 87.7% of HIV patients, 71% of those with diabetes and 68% of those with 
hypertension [2].  Whilst not including specific data on patients with co-existing chronic 
disease, this study showed that integrating chronic disease care was feasible.  It also found 
that the service was well-accepted by patients and that health care staff used similar skills 
(particularly those regarding chronic disease and adherence) in managing NCDs and HIV, 
demonstrating an overlap and potential increased efficiency in use of staff.   Another study 
in Kenya also found that up-skilling staff to provide a cardiovascular disease service in an 
HIV setting was feasible and well-accepted by staff [16].  Importantly, a large study from 
Uganda combined NCD care into existing HIV services and found this to be a feasible model 





One method by which ART scale-up has been successfully achieved in South Africa is the 
Adherence Club (“club”) system whereby PLHIV receive their antiretroviral mediation 2-
monthly in a counsellor-led non-clinic environment run by trained counsellors.  To qualify 
for the clubs, patients must be virally suppressed (defined as ≤400 copies/ml) and have 
been on their antiretroviral mediation for at least six months.  Within this system, patients 
meet five times a year for a weight, a symptom check and to receive their pre-packed 
medication.  Each club member receives an annual blood test followed by a clinical visit at 
which results and any symptoms are reviewed by a clinician.  Outcomes to date have been 
good, albeit on an observational rather than analytical level.   A recent retrospective cohort 
analysis of clubs in the Cape Town health district showed retention of 95.2% (95% CI, 94.0-
96.4) at 12 months and 89.3% (95% CI, 87.1-91.4) at 24 months after club enrolment, 
together with 94.1% (95% CI, 91.6-96.0) viral suppression (defined as ≤400 copies/ml) at 
month 28 after joining the club. [18].  These encouraging outcomes (although still 
reasonably short-term with a median time in clubs in this study of 1.1 years) add weight to 
the argument for using ART scale-up models to encompass those patients with co-existing 
NCDs and HIV.  In addition, such patients are currently excluded from the club system and 
so are an increasingly large under-served population.  A retrospective descriptive study 
carried out in Kenya assessed retention, amongst other indicators, in patients enrolled into 
clubs.  These clubs comprised patients with HIV, hypertension or diabetes or various 
combinations of these.  Retention in the club system was good, at 94.5% at 1 year, and in 
addition there was a high degree (99%) of compliance with protocols, demonstrating early 
feasibility of these mixed-disease clubs [19].   
 
Building on this evidence, various facilities within Cape Town have informally implemented 
co-morbidity clubs over the last few years. These initiatives (based on the ART club model 
but serving those patients with both HIV and diabetes and/or hypertension) have been 
pragmatic in nature, often having been developed at a facility level as a consequence of the 
increasing need to address the needs of this population.  They are thus somewhat 
fragmented with no standardised guidance or model, and outcomes have not as yet been 
assessed.  There is therefore a basic need to evaluate these co-morbidity clubs to inform 
best practice at a local level.  This study hopes to achieve this by analysing routinely 
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collected data from both the HIV-only clubs and the newer co-morbidity clubs at Gugulethu 
Community Health Centre (CHC) to compare outcomes, specifically retention in the club and 
viral suppression.  This will address the current lack of analytical research on this topic.  By 
comparing these newly-implemented co-morbidity clubs to the successful and established 
HIV-only club model, it is hoped that evidence will be generated to inform not only policy 
locally but also the wider potential to integrate NCD and HIV services at a national or global 
level. 
 
Purpose of the Study 
 
This study seeks to compare key outcomes between HIV-positive adults enrolled in a HIV-
only adherence club and those enrolled in a co-morbidity adherence club (for those with 
diabetes and/or hypertension in addition to HIV) during 2016.  The key outcomes are 
retention in the club system and viral suppression.   
 
Primary objectives 
• To compare club retention at 12 months amongst adults enrolled into the HIV-only 
adherence club model compared to those enrolled into the co-morbidity club model  
• To compare the proportions of adults who have viral suppression, defined as not 
having experienced a club viral load > 400 copies/ml within 12 months of enrolment, 
between club models 
 
Primary Hypotheses  
• There will be no difference in retention proportions between the two club models.  
• There will be no difference in proportions of adults with viral suppression between 






• To describe reasons for being sent back to clinic care, overall and by club model.    
• For those enrolled into co-morbidity clubs, to describe primary outcomes (retention 






The proposed study design will be a retrospective cohort study using clinical data routinely 
collected by the HIV service at Gugulethu CHC.  Data from the Gugulethu clubs have been 
collected since their inceptions in June 2012 (for the HIV-only clubs) and February 2016 (for 
the co-morbidity clubs).   These data comprise patient demographics such as sex and age as 
well as scheduled and attended club visit dates and current retention status within the club. 
    
For the purposes of this study, the data used will be that concerning all adults enrolled into 
a club in 2016 (either HIV-only or co-morbidity).  The date of enrolment will be defined as 
the date of the first attended club appointment and the study follow-up time will be 12 
months post-enrolment plus a seven day grace period.  Thus routine data will be used from 




The proposed study will use routinely collected data from the Gugulethu HIV clinic and the 
associated off-site clubs.   
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Gugulethu has a population of approximately 100 000 (with a catchment area population of 
approximately 400 000) and is predominantly of low-socioeconomic status.  The vast 
majority of the population uses free local public sector health services.  By the end of 
December 2017, approximately 5875 adults on antiretroviral therapy (ART) were under the 
care of the HIV services at the Gugulethu CHC (encompassing both the clinic and the clubs), 
with approximately 60% of these adults being retained in club care (from local data). Since 
the implementation of clubs at Gugulethu in June 2012, the number of adults retained in 
club care has steadily increased.  From January 2014 until December 2017, the number of 
adults retained in club care increased by 45% from 2420 to 3509 (from local data).  
 
The Club Model of Care 
 
There are, as of December 2017, 119 HIV-only clubs operating at Gugulethu CHC together 
with seven co-morbidity clubs and two adolescent clubs. The adult clubs meet in the nearby 




The local standard of care is clinic-based care from ART initiation, with potential club 
referral from six months post-initiation for those patients who are virally suppressed and 
have no co-morbidities that require additional health care.  Club referral is at the clinician’s 
discretion.   
 
Each club consists of around 30 individuals and meets every two months with the exception 
of the December/January holidays when the appointment interval is four months.  The clubs 
are run by counsellors who give a health promotion and adherence talk, promote condom 
use, weigh and check symptoms for each club member and dispense two months of pre-
packed ART (four months over the December/January holiday period) at each visit.   Each 
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club member receives an annual blood test visit (referred to as a Blood Visit) at which point 
a professional nurse performs routine phlebotomy for viral load and ART safety bloods.  The 
following visit is a Clinical visit, at which the nurse checks the blood results and performs a 
clinical assessment.  The remaining visits are known as Standard.  Patients in clubs may send 
someone (a “buddy”) to collect their ART for them, but this is permitted only every alternate 
visit and never on a blood or clinical visit.  If a patient misses a club visit, there is a grace 
period of seven days after the scheduled session for them to collect their medication.  Those 
who have not collected their medication within this period are identified as DNA (Did Not 
Attend).  These patients are followed up by the counsellors via phone calls and home visits, 
depending on resources, and are removed from club.  Patients are removed from club and 
sent back to clinic (BTC) if they have a high viral load (>400 copies/ml), are pregnant, or have 




These clubs are for those patients on both ART and medication for diabetes and/or 
hypertension, all for more than six months.  The usual HIV inclusion criteria still apply, as per 
the HIV-only clubs, but there are additional disease indicator criteria as shown in Table 1.  
To enable correct inclusion, a screening form was implemented in April 2016 (see Appendix 
A).  Patients are removed from co-morbidity clubs for the same reasons as the HIV-only 
clubs but also if their chronic disease indicators are above prescribed thresholds, as shown 
in Table 1.  Co-morbidity clubs are run by club counsellors with additional training in health 
promotion and lifestyle advice pertaining to diabetes and hypertension.  The structure of 
visits in the co-morbidity clubs is a little different from the HIV-only clubs, most obviously in 
that there are two scheduled annual clinical visits rather than one, and that a Clinical Nurse 





Table 1. Comparison of Club Models  
 
AREAS OF CARE CLUB MODEL 
 HIV-ONLY CLUB CO-MORBIDITY CLUB 
Eligibility 
 
• ≥6 months on ARVs 
• Viral load < 400 copies/ml 
• No other co-morbidities 
• CD4 > 100 
• Not pregnant 
• ≥6 months on ARVs 
• Viral load < 400 copies/ml 
• ≥6 months on medication for 
diabetes and/or hypertension 
• CD4 > 100 
• Not pregnant 
• BP (mmHg) less than target 
o 150/95 for hypertension  
o 150/90 for diabetes 
• HbA1c < 9% for diabetes 
• Creatinine Clearance >50 ml/min 
(or eGFR† > 60)  
Criteria for Removal  • DNA 
• Viral load > 400 copies/ml 
• Pregnant 
• Symptoms meriting further 
assessment 
• DNA 
• Viral load > 400 copies/ml 
• Pregnant 
• Symptoms meriting further 
assessment 
• BP > 160/100 for all 
• HbA1c > 10% for diabetes 
• Step up in meds needed 
Structure of Visits • Standard 
• Standard 
• Blood (viral load, safety bloods) 







o  Viral load, safety bloods, 
creatinine, cholesterol if 
previous cholesterol > 5 
mmol/l for all 
o HbA1c for diabetes 
• Clinical 1  
o Blood results, random 
glucose, BP for all 
• Standard  
• Standard 
• Clinical 2  
o BP for all 
o Foot screen, random glucose, 
urine, date for retinal 
screening for diabetes 
Staff present • Standard Visits - Counsellors 
• Blood and Clinical Visits – 
Professional Nurse 
• Standard Visits - Counsellors 
• Blood and Clinical Visits – Clinical 
Nurse Practitioner 





Study participants will be HIV positive persons referred to attend an HIV-only or a co-
morbidity club at Gugulethu CHC in 2016. 
   
Inclusion criteria 
 
• Age 18 or older  




• First viral load blood test scheduled within 121 days (four months) of the first club 
visit 
• No scheduled club clinical visit within the follow-up period of 1 year (plus seven days 
grace period) 
• Those enrolled into adolescent clubs 
 
The first two exclusion criteria are in place for the following reasons:  
All those enrolled into the co-morbidity clubs had a scheduled first viral load blood test at 
four months after enrolment.  This is because all these clubs were newly implemented (see 
Table 2).  However, those enrolled into the HIV-only clubs had their first scheduled viral load 
blood tests at any point from enrolment to 12 months, due to the nature of some of these 
clubs existing prior to 2016.  To adjust for this, individuals enrolled in the HIV-only club 
system who had a viral load blood test prior to four months (121 days) will be excluded.   
For similar reasons, some of those enrolled into HIV-only clubs did not have a scheduled 
clinical visit within the 12 months of follow-up (due to the four month visit interval towards 
the end of the year) and so these individuals were also excluded.   
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Data Collection  
 
Standard of Care  
 
Each club (HIV-only and co-morbidity) visit is recorded, as per the Gugulethu CHC standard 
of care, on a paper register, held by the club counsellors and kept locked in the club room in 
the clinic when not in use.  A data clerk captures the data on a weekly basis into a password-
protected Excel spreadsheet.  The data is backed up on a weekly basis and the computer 
used is kept in a locked room at the clinic.  The data clerk has undergone training in data-
capturing as well as Good Clinical Practice and ethical research conduct, and is supervised by 
a UCT staff member to ensure accuracy of data capturing.  
 
The co-morbidity club data collection involves additional indicators, and these are recorded 




Electronic records, as mentioned above, and patient clinic folders (particularly for those 
enrolled into the co-morbidity clubs) will be used for this proposed study. This study data 
will only be accessed by the study investigators and will be password-protected following 
standard password safety procedures.  The routinely collected data, as per standard of care, 
contain identifiers (names and folder numbers) but these will be removed, and replaced 
with anonymous identifiers, once the data have been cleaned and are ready for analysis.  In 
the case of both clubs, patient clinic folders and laboratory records may be used to address 
missing data.  All study investigators are trained in Good Clinical Practice and ethical 







The total number of individuals included in the study will be all those enrolled in clubs in 
2016 and who fulfilled the criteria as previously described. This will be 602 in total; 501 from 
HIV-only clubs and 101 from co-morbidity clubs.  This represents all patients currently 
enrolled in the comorbidity clubs thus sample size estimation was not needed. However, 
this sample size will give 90% power to detect a 15% difference in retention between HIV-
only and co-morbidity clubs using a two-sided alpha of 0.05 and assuming retention in the 
HIV-only club of 85% (from programme data). 
  
Primary outcome analyses 
 
The primary outcomes are retention in club care at 12 months post-enrolment and viral 
suppression (no club viral load >400 copies/ml within 12 months post-enrolment). Reasons 
for not being retained in club will be defined based on the club standard of care as follows: 
DNA (Does Not Attend), BTC (sent Back to Clinic), TFO (is Transferred Out of the club) or RIP 
(passed away).  In addition, age, sex and time on ART for each patient will be abstracted 
from the club registers and patient folders.   
The analyses will be based on pure-count methods, beginning with a description of baseline 
variables (both demographic and clinical) by club model.  Descriptive statistics will include 
medians with interquartile ranges, means with standard deviations, and proportions. 
Comparisons of distributions and retention proportions by club model will employ t-, rank-
sum, chi-squared or Fisher’s exact tests, as appropriate.   The date assigned to loss of 
retention will be the first scheduled club date at which the patient is recorded as DNA, BTC, 
TFO or RIP.  The date assigned to the loss of viral suppression will be the date of the first 
post-enrolment club viral load blood test showing >400 copies/ml.  In addition, survival 
analysis will be used as a secondary approach to primary outcome data analyses and will 
include Kaplan-Meier estimates of the proportion of retained patients by club model and a 




Secondary outcome analysis  
 
The secondary analyses will describe known reasons for non-retention overall and by club 
model.  Univariable and multivariable logistic regression models, overall and by club model, 
will be used to examine predictors of the primary outcomes of interest  
 
Throughout the analyses, statistical tests will be 2-sided at α=0.05.  Model fit will be 
compared using the AIC, and all modelling will employ standard diagnostic procedures [20]. 
 




As this is a retrospective cohort study using data previously collected as per the Gugulethu 
CHC standard of care, it is a minimal risk study.  However, there still remain potential risks 
should loss of confidentiality occur during study data collection and analysis.  Specific 
measures to minimize this risk include confidentiality training for all personnel involved in 
data collection and analysis.   Anonymous identifiers will be used during all study data 
collection and analysis and all electronic records will be kept in password-protected files.   




There are no specific direct benefits to the patients in this study as the data will be collected 
on patients who have already been enrolled in a club model at a clinician’s discretion as per 
the standard of care.  However, there are indirect benefits.  The HIV-only clubs already have 
evidence showing, at minimum, comparable viral suppression and retention rates compared 
to clinic care.  So, by comparing the co-morbidity clubs to the standard of these existing 
clubs, it will be possible to potentially identify whether these co-morbidity clubs are an 
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optimal strategy for delivering care to adults with co-morbidities.  There is clinical equipoise 
regarding co-morbidity club outcomes and, if shown to have successful outcomes, there is 
potential for this club model to be scaled-up throughout Cape Town, the Western Cape 
Province, and across South Africa. This would potentially result in providing an integrated, 
more efficient service to this currently underserved population.  To this end, the 
involvement of policy makers involved in HIV care and treatment will help maximize the 
indirect benefits of the study through strengthened public sector health care services for 
individuals affected by co-morbidity as described.   
 
Informed Consent process 
 
No specific informed consent will be taken from participants, as the data being analysed is 
routinely collected by the Gugulethu CHC as part of the standard of care.  For the same 
reason, there will be no compensation for participants.  Of note, all patients who attend the 
Gugulethu CHC HIV services (from where patients are referred to the clubs) sign a simple 
consent form informing all patients that standard of care data will be captured for research 
purposes and that their confidentiality will be maintained (see Appendix B). 
 
Privacy and Confidentiality 
 
As previously discussed, confidentiality will be preserved throughout the study.  All routine 
standard of care data collection was done in a closed room at the Gugulethu CHC, and the 
same procedures will be followed for any addition data collection necessary to fill address 
missing data.  The clinic-based data-entry clerk and all investigators have been trained in 
Good Clinical Practice (GCP) and ethical research conduct to ensure that they uphold 
confidentiality on all study information.  The data will contain anonymous participant 
identifiers and all data sets are, and will continue to be, password-protected and stored on a 







As previously discussed, this study is using routinely collected data from these two 
Gugulethu club models which will be anonymised and password-protected.  No additional 
contact with patients will be conducted. Approval for this research is being sought from the 
University of Cape Town Human Research Ethics Committee. 
 
Following from the successfully implemented HIV-only clubs, the co-morbidity clubs were 
implemented pragmatically in various facilities in the Cape Town area based on a perceived 
need to provide a service for those HIV infected patients who also had diabetes and/or 
hypertension.  It was soon after implementing the HIV-only clubs that this need was 
perceived.  It was agreed at the Steering committee (an official body convened by the 
Western Cape Government) that these HIV patients with co-morbidities could be put in 
clubs as long as clinicians took responsibility for ensuring the extra review.  Following this, 
Dr Cathy Kalombo, at Gugulethu CHC, implemented specific co-morbidity clubs at the 




Use of information and publications 
 
The proposed study will be submitted as a mini-dissertation in partial fulfilment of the 
requirements for Masters in Public Health degree at the University of Cape Town.  A 
publishable manuscript describing the findings of this study will be prepared for submission 
to a relevant peer reviewed journal for publication.  The proposed study results will also be 
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The Problem of Co-morbidity 
 
Globally, deaths from non-communicable diseases (NCDs) are increasing both in number 
and as a proportion of all deaths, with the majority occurring in low and middle income 
countries [1].  On top of this public health concern, the prevalence of HIV in South Africa 
continues to rise, largely due to the successful anti-retroviral therapy (ART) roll-out 
programme, and thus a cohort of ageing adults with chronic HIV infection is emerging [2].  
There is therefore a growing number of people living with HIV (PLHIV) who also have one or 
more NCDs.  Currently, this population is poorly served by vertical programmes and there 
are few examples of integrated care.   
 
Models of Care 
 
The scale-up of the ART programme has generally been deemed to have been successful 
and so there is a growing interest in harnessing this programme to address the needs of this 
new co-morbid population by integrating NCD care into the existing HIV health system [3].   
One model of care by which ART scale-up has been successfully achieved in South Africa is 
the club system, whereby PLHIV receive their ART 2-monthly in a counsellor-led 
environment [4].  On the back of the success of this and other global programmes 
integrating NCDs and HIVs, various facilities in Cape Town have recently informally 
implemented co-morbidity clubs catering for those with both HIV and one or more NCDs, 
most commonly diabetes and hypertension.  
 
The Research Gap 
 
There is very little research evidence regarding outcomes of integrated models of care, with 
few South African analytical studies looking at outcomes for this specific population.  The 
primary aim of this review is to explore and appraise the existing research on integrated 
models of care for HIV, hypertension and diabetes.  This review will briefly describe the 
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landscape of HIV and NCDs before synthesising the available literature on integrated models 
of care.  This review will set the background for the manuscript which focuses on describing 
the local implementation of co-morbidity clubs and then comparing various outcomes 
between adults in these clubs (who have both HIV and hypertension and/or diabetes) with 
those in the HIV-only ART clubs.    
 
Literature Review Search Strategy 
 
 
Full text papers published in English, from January 2000 – March 2018 were included. The 
full strategy is outlined below in Table 1.  Included studies focused on integrated care of 
adults with both HIV and hypertension and/or diabetes, and were discussed in the following 
themes: the public health burden, arguments for integrated care, the feasibility of 
integrated care, benefits and challenges of integrated models of care, and the existing club 


























Table 1.  Literature Search 
 
Database Number Strategy 
Pubmed 1 MeSH HIV Infection OR MeSH Acquired Immunodeficiency 
syndrome OR MeSH HIV 
 2 HIV OR Human Immune Deficiency Syndrome OR Acquired 
Immune Deficiency syndrome OR Immunodeficiency syndrome 
 3 1 OR 2 
 4 MeSH Adult 
 5 Adult 
 6 4 OR 5 
 7 MeSH Antiretroviral Therapy, Highly Active OR MeSH Anti-
Retroviral Agents 
 8 Antiretroviral OR Anti-retroviral OR Antiviral OR Anti-HIV OR ART 
OR HAART OR ARV 
 9 7 OR 8 
 10 MeSH Medication Adherence OR MeSH Patient Compliance 
 11 Adherence OR Compliance OR Medication Persistence 
 12 10 OR 11 
 13 Model* of care OR Club* OR Adherence Club* 
 14 MeSH Diabetes Mellitus OR MeSH Hypertension 
 15 Diabetes OR Hypertension OR Non-communicable diseases 
 16 14 OR 15 
 17  Integrated HIV care  
 18 MeSH Delivery of Health Care  
 19 Integrated HIV care OR MeSH Delivery of Health Care 
 20 3 AND 6 AND 9 AND 12 AND 13 AND 16 AND 19* 
Cochrane  HIV AND (hypertension OR diabetes) 




 HIV AND Hypertension AND adherence  
HIV AND Diabetes AND adherence 
Conferences  Sites searched included IAS, AIDS2014 and CROI 
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The Public Health Burden 
 
The burden of NCDs 
 
This burden of NCDs can be enumerated in terms of prevalence, incidence, mortality and 
morbidity.   
 
Diabetes is increasing in prevalence.   It is estimated that around 16 million adults in Africa 
were living with diabetes in 2017 and this number is expected to rise to around 41 million by 
2045 [5].   Regarding hypertension, the trend in prevalence is less clear but, as of 2015, 
stands at 26.1% for women and 27.4% for men in South Africa [6].  There is thus a 
substantial burden of both mortality and morbidity from NCDs in South Africa.  
 
The estimated incidence of diabetes in people with HIV varies widely between studies and 
the data available are limited.  A recent African systematic review reports a combined 
incidence rate of 17.4 per 1000 person years and concludes that this seems no higher than 
in those without HIV [7].  Regarding hypertension, a prospective cohort study of people with 
HIV in Tanzania recently found an incidence rate of hypertension of 120 per 1000 person 
years [8].  
 
Globally, deaths from NCDs are increasing in number, killing 40.5 million people in 2016, 
with 17.9 million of these deaths being attributable to cardiovascular disease and 1.6 million 
to diabetes.  In South Africa, 39% of deaths were caused by NCDs in 2010, with the absolute 
number of deaths due to NCDs being similar to the number due to HIV and TB combined [9].  
By 2030, NCDs are predicted to be the biggest cause of death in Africa [9].  
 
Whilst Global Disability-Adjusted Life Years (DALYs) remained stable from 1990 to 2010, the 
proportion of these DALYs accounted for by NCDs increased from 43% in 1990 to 54% in 
2010 [10].  In addition, the global distribution of NCDs is heterogenous, with low- and 
middle-income countries shouldering the greatest burden.  In fact, 80% of the deaths due to 
chronic disease occur in these countries [1].  In addition, on this background of mortality 
transition there exists the undiminishing prevalence of HIV. 
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The burden of HIV 
 
Globally, as of 2017, there were around 36.9 million PLHIV and 940,000 HIV-related annual 
deaths [11].   An astounding 19% of these PLHIV are living in South Africa, and the HIV 
prevalence in the country is certainly not decreasing [11].   A STATS SA release in 2017 found 
a mid-year HIV prevalence of 12.6%, compared with 12.1% in 2012 and 10.6% in 2008 [12, 
13].  This increase in prevalence, despite a decrease in new HIV infections since 2010, is due 
to the introduction and subsequent scale-up of ART which has decreased mortality and 
increased life-expectancy not only in South Africa but world-wide [14, 15].  In South Africa, 
ART became widely and freely available in 2004 and a large cohort study from KwaZulu-
Natal showed an overall life-expectancy (not just in those with HIV) increase of 11.3 years 
from 2003 to 2011 [2].     
 
This welcome drop in HIV mortality is, however, generating a new health challenge – that of 
the increasingly large and ageing cohorts of PLHIV who are less vulnerable to HIV-related 
opportunistic infections but more vulnerable to NCDs.   In fact, HIV has been recognised by 
the WHO as being a chronic disease as it fits the description of a condition requiring ongoing 
management over years [16].  South Africa is therefore increasingly experiencing the dual 
burdens of NCDs and HIV, chronic diseases which are not without their similarities and 
which are often experienced as comorbid diseases. 
 
Dual burden of HIV and NCDs 
 
As can be inferred from the WHO’s definition of HIV as a chronic disease, HIV shares some 
characteristics with other chronic diseases.  The main risk factor for HIV infection is 
behavioural (unsafe sex) as are the main risk factors for NCDs (alcohol use, smoking, 
obesogenic diet, inactivity) [17].  Whilst the risk factors themselves differ, the behavioural 
interventions necessary to try and modify these lifestyles have similarities.  Both HIV and 
NCDs tend to be progressive over time and effective treatments of both include an 
emphasis on self-management with community support and a need to monitor adherence 




As well as the shared characteristics, PLHIV are thought to be at increased risk of developing 
NCDs over time due to several reasons: the virus itself via chronic inflammation 
mechanisms, ART (both the incidence of diabetes and the prevalence of hypertension have 
been shown to increase with cumulative exposure to ART), and the simple fact of ageing ie 
survival from previously deadly HIV-related opportunistic infections and thus vulnerability to 
NCDs [19–23].  It is predicted that the majority of PLHIV (up to 84%) will have at least one 
NCD by 2030 [24]. Therefore, there are not only shared characteristics between NCDs and 
HIV but there appears to be an increased prevalence of NCDs amongst PLHIV which further 
drives up the number of people with these comorbidities.   
 
There have been a number of studies looking at the question of the prevalence of NCDs in 
PLHIV.  A cross-sectional survey in Cambodia found that, of 510 adults attending HIV clinics, 
8.8% had diabetes and 15.1% hypertension [25].  Similar studies in Malawi and Zimbabwe 
showed somewhat differing results with the prevalence of co-morbidity (with common 
NCDs) in the HIV population being 26.6% and 15.3% respectively [26, 27].  A 2012 systematic 
review looked at African and Asian populations and assessed the magnitude of NCD and HIV 
co-morbidity.  The results showed that the prevalence of diabetes was less than 5% in all the 
included studies and that of metabolic syndrome 13-28%  [28].  There are three basic 
limitations to these data – firstly all studies included were cross-sectional therefore there is 
no temporality thus no basis on which to judge causality. Secondly there are no comparison 
groups and thirdly there is no Africa-specific disaggregation.  There exists one prospective 
study which found an incidence of diabetes in PLHIV of 5.72 (5.31-6.13) per 1000 PYFU but 
this is relatively old (2008) and contained no African cohorts [19].  Regarding comparison 
groups, some of the clearest evidence comes from Italy where one case-control study 
showed a significantly higher prevalence of NCDs in PLHIV compared to HIV-negative adults 
and another found a significant two-fold increased prevalence (4.1% vs 2.5%) of diabetes in 
those with HIV compared to those without [29, 30].  
 
So not only are these chronic diseases independently increasing in prevalence but there is 
an increase in co-morbidity over and above that expected, due to this excess of NCDs in 
PLHIV.  In addition, it is thought that these comorbidities actually have multiplicative 
damaging effects on health outcomes, and are thus best managed by primary care clinicians 
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skilled in this particular area [31].  Because of the above-mentioned increasing population, 
the shared principles of management and the specific health-care needs, there is growing 
interest and urgency in implementing integrated care for this population.  However, it is not 
only this that points to the benefits of integrated care.  The need for horizontal programmes 
can also be supported from the point of view of minimising both the individual and the 
health system burden.   
 
The Arguments for Integrated Care 
 




Patients with co-morbidities carry a large burden in terms of understanding their diseases, 
clinic appointments and medication. Those with co-morbidities have been shown to be at 
increased risk of poor adherence due to the large numbers of medications prescribed for 
each individual involved, with the degree of this polypharmacy being a predictor of 
mortality  [32, 33].  It has also been shown that patients with co-morbidities use health care 
more frequently, and suffer poorer outcomes [31].   One qualitative study from the USA, 
specifically carried out on those with both HIV and either diabetes or hypertension, found 
that comorbidities frustrate patients, with poor understanding exacerbating adherence 
problems [33].   In addition, a recent South African qualitative study assessed the 
experiences of patients with both HIV and diabetes and found a dissatisfaction with having 
to attend separate clinics for HIV and diabetes as well as difficulty managing the pill burden 
[34].   
 
Also of note, there is evidence that HIV clinicians are not always comfortable treating 
general comorbidities [35].  Such individuals currently have to attend multiple appointments 
and are often seen by multiple different health professionals thereby putting extra strain on 
the achievement of adherence and retention, compromising optimal care as well as 
resulting in a suboptimal patient experience in terms of time spent accessing health care 
[36].  An all-too-common outcome is patient deferral of vital routine visits.  Integrated 
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models of care would allow individuals with both HIV and NCDs to receive care from a 
clinician specifically trained in this population and would reduce the individuals’ burden of 
clinic visits. 
 
Health System Benefits 
 
Co-morbidities also place a burden on the health system that could, at least in part, be 
alleviated with integrated care.  It is thought that integrated management would be more 
cost-effective and efficient than multiple vertical programmes [17].  Health systems, in low- 
and middle- income countries especially, are already under-resourced and so any increased 
efficiency in cost, time, resources and staff is much needed [37].  It has also been argued 
that integrated management potentially increases community self-reliance [18].  
 
The Call for Research 
 
There are many arguments for integrated care: innate shared characteristics and 
management needs, an increasingly large population, a need to optimise patient adherence 
and experience, potentially improved clinical care and lastly health system efficiencies.  
Horton in the Lancet argues that HIV and NCDs should not be seen as separate entities in 
research, and Narayan et al describes a key research priority entitled,  “Development of 
innovative and effective models of integrated NCD and HIV care” [38, 39].  In addition, a 
report from South Africa in 2009 called for a national initiative for integrated care and a 
recent Lancet article describes HIV and NCDs as “increasingly intertwined” and highlights 
the urgent need for research (including health system research) on this population in sub-
Saharan Africa [40, 41]. Questions must thus be asked about the current evidence regarding 
models of NCD and HIV co-management, how to best assess these models, and whether 









The Feasibility of Integrated Care 
 
Co-management of HIV and NCDs 
 
A  retrospective cohort study from the USA looked at the associations in women (from 2006 
to 2014) between HIV status and the control of any coexisting diabetes and/or hypertension 
[42].  The results showed better control of these NCDs in HIV positive women compared to 
HIV negative women.  This better management was postulated to be due to an increased 
propensity for HIV positive women to be receiving routine health care, often with a 
consistent provider.  Another retrospective cohort study, more generalisable to the African 
context, compared NCD outcomes over one year between HIV positive and HIV negative 
adults in Nairobi, Kenya [43].  The results showed no significant differences in blood 
pressure or HbA1c between the two groups, again supporting the idea that it should be 
possible to integrate NCD and HIV care together in a primary care clinic.    
 
Harnessing the HIV Infrastructure 
 
A UNAIDS report from 2011 argues that this integration will be best achieved by leveraging 
the HIV experience and describes an Ethiopian before and after study in which local existing 
HIV approaches (including record-keeping approaches, staff training etc) were used and 
outcomes (such as increased monitoring and assessment of adherence) were thereby 
improved [23, 44].  The scale-up of the ART programme has generally been deemed to have 
been successful, especially in South Africa, and so there is potential to leverage this 
programme to manage those with both HIV and NCDs [4].  Using the existing HIV 
infrastructure enables harnessing of this successful programme in terms of location, staff 
expertise, multi-disciplinary teams, adherence and retention support, monitoring and 
evaluation, task-shifting, community-based care as well as patient acceptance.  It also has 
the potential to limit extra costs and staffing, and is relatively well-funded especially when 
compared to funding for NCD programmes [36].  Attempting to collate the existing evidence 
on models of integration, a recent literature review described 15 such programmes in low 
income countries.  The results varied from model to model, but the review concluded that it 
is feasible to use the existing HIV infrastructure and systems to provide care for those with 
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NCDs in an integrated environment [45].   There is also some evidence that individual 




There is little clear evidence on the optimum outcome measures for this co-morbid 
population.  A study from Uganda assessed disease control (in terms of viral suppression, 
blood pressure control and HbA1c control as appropriate) in those with both HIV and 
hypertension and/or diabetes who attended multi-disease community health fairs over 3 
years [46].  The results showed that 67-69% of those with HIV and hypertension or diabetes 
achieved control compared to 90% of those with HIV alone, and thus the authors argue for 
the importance of using a composite endpoint [47].  However, there is also evidence that 
that determinants of adherence don’t differ widely within patients and that there is a strong 
correlation between ART adherence and adherence to medication for NCDs [48, 49].   In 
addition, a USA study looked at the association between poor HIV control and poor control 
of diabetes or hypertension.  Their linear regression analysis demonstrated a link and they 
conclude that this correlation points to a common factor of poor adherence [50].  It is 
therefore likely that markers of ART adherence (such as viral load) can help predict 
adherence to NCD medication and so such HIV outcomes can provide useful proxy markers 
of overall outcomes in this population.   So, having established reasonable feasibility of co-
management and of harnessing the existing HIV infrastructure as well as having discussed 
outcome measurement, it is important to look for more specific evidence related to 
outcomes from these models.   
 
Benefits and Challenges of Integrated models of care 
 
There is a startling lack of large-scale models of any chronic care in low- and middle-income 
countries [36].  There is therefore little outcome evidence currently for the co-morbid 
population, with the few published studies being descriptive or implementation-focused 
[45].  However, some early evidence has been encouraging, with most existing studies in 
Africa and Asia finding integrated care for HIV and NCDs to be acceptable and feasible for 




Benefits for the Clinic Staff and Health Systems 
 
Benefits for health care workers were shown in a study from Kenya that found that up-
skilling these workers to provide a cardiovascular disease service in an HIV setting was 
feasible and well-accepted by staff [53].   There is also some evidence of potential increased 
efficiency in use of staff.  For example, in Cambodia, chronic disease clinics (accepting adults 
with HIV, diabetes or hypertension or any combination of these) were set up with the aim of 
treating HIV and NCDs within one system and using complementary adherence support 
strategies.  It was found that health care staff used similar skills (particularly those regarding 
chronic disease and adherence) in managing NCDs and HIV, demonstrating an overlap and 
possible improved efficiency [51].  Adding to the evidence on increased efficiency is a study 
from Malawi of the implementation of an integrated chronic care clinic which found that no 
additional human or financial resources were needed compared to treating the chronic 
diseases separately [52].  
 
Benefits for the Patients 
   
The Cambodian study mentioned above demonstrated reasonable retention at 24 months 
of care (87.7% for PLHIV, 71% for those with diabetes and 68% for those with hypertension) 
which is comparable to or better than African retention rates for those with HIV alone which 
stands at 65% of adults retained at 3 years [54].  It also found that the services were well-
accepted by the patients.  An African study with similar findings comes from Uganda and 
found that combining NCD care into existing HIV services was a feasible model for managing 
those with co-morbidity, reporting improved NCD diagnosis and management since 
implementation of this integrated approach [46].   This finding was backed up by the afore-
mentioned Malawian case-control implementation study which described the set-up of 
chronic disease clinics providing care for HIV and common NCDS.  This study also found early 
evidence, albeit it descriptive, that an integrated approach was efficient and reduced some 






However, some challenges have been recorded.  A case study in South Africa evaluated the 
2011 pilot implementation of an integrated chronic disease management (ICDM) model, the 
aim of which was to use existing HIV programmes to also manage those with NCDs.  
Although this pilot was situation-specific with limited generalizability, it did fail to find the 
model sufficiently acceptable from the perspectives of both patients and staff with many 
reported inadequacies such as poor defaulter-tracing, equipment and drug availability [55].   
Of note, a later interrupted time-series study on the ICDM model, published in 2017, found 
a small but significant improvement in CD4 count and blood pressure over time but no 
overall clinical benefit [56].   Other studies also mention various challenges to the 
implementation of integrated care [36, 53, 57].   These include the need for increased 
human resources, the increase in patient demand, drug stock-outs and poor infrastructure 
and equipment amongst others.  Despite these challenges, the majority of the patchy 
evidence available points to the achievability of integrated care.  Some of the most 
compelling early evidence for the feasibility of integrated care comes from Kenya and is 
based on the club system developed in South Africa.  
 
The Club Model 
 
The club model was developed in South Africa from 2007 onwards and is a system whereby 
PLHIV (who are stable on their medication but have no other co-morbidities) receive their 
antiretroviral mediation two-monthly in a counsellor-led non-clinic group environment run 
by trained counsellors.   A recent retrospective cohort analysis of such clubs in the Cape 
Town health district showed retention of 95.2% (95% CI, 94.0-96.4) at 12 months and 89.3% 
(95% CI, 87.1-91.4) at 24 months after club enrolment, together with 94.1% (95% CI, 91.6-
96.0) viral suppression (defined as ≤400 copies/ml) at 28 months after club enrolment [5].  
Although there was no suitable comparison group in this study, and the definition of 
retention included those who left club but continued clinic care, these retention rates were 
shown to be well above South African estimated retention rates of around 72% at 4 years 
post ART-initiation [58].   Of note, the retention remained comparable (77.6%) if one used 
the stricter definition of retention in the club system itself.  These good outcomes (although 
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still reasonably short-term with a median time in clubs in this study of 1.1 years) add weight 
to the argument for using ART scale-up models to encompass those patients with co-existing 
NCDs and HIV.  In addition, the club model has been shown to be acceptable to patients and 
more cost-effective than clinic care [59] [60].   
 
The Kenyan Experience 
 
Building on the success of the South African model and to address the agenda of integrated 
care, Medication Adherence Clubs (MACs) were implemented in Nairobi, Kenya with the aim 
of using this club system to provide care for adults with one or any combination of 
hypertension, diabetes and HIV [61].   A study of 1432 such adults found a high retention 
rate of 96.5%, a high degree of compliance (99%) to protocols and that only 2% of club 
patients had to be referred back to the clinic for medical reasons during the one year follow-
up time.   Although this study was descriptive only, nurse- rather than counsellor-facilitated, 
and provided no specific data regarding co-morbidities, the sample size was reasonable and 
it appears generalisable to the South African context in terms of the population being from 
a resource-constrained urban area.  A later qualitative study on the same population found 
MACs to be acceptable to both patients and health care workers, the main benefits being 
cited as reduced waiting time and number of appointments [62].  This early encouraging 
evidence regarding models of integrated care together with the unmet need for effective 
care for this growing co-morbid population has led to the informal implementation of co-
morbidity clubs in various facilities within Cape Town. 
 
The Co-morbidity clubs 
 
The Cape Town co-morbidity clubs have been implemented pragmatically at a facility level, 
largely due to an increase in individuals who were excluded from HIV-only ART clubs due to 
hypertension and/or diabetes.   With the approval of the Provincial Department of Health 
Steering Committee, the co-morbidity clubs at Gugulethu Community Health Centre, Cape 
Town started enrolling patients with both HIV and hypertension and/or diabetes from 
February 2016, with the admission criteria following that of the HIV-only ART clubs with the 
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addition of chronic disease criteria.  Table 2 outlines the two local club models in terms of 
eligibility, removal criteria, visit structure and human resources. 
 
Table 2.  Comparison of the Club Models  
 
AREAS OF CARE CLUB MODEL 
 





• ≥6 months on ARVs 
• Viral load < 400 copies/ml 
• No other co-morbidities 
• CD4 > 100 
• ≥6 months on ARVs 
• Viral load < 400 copies/ml 
• ≥6 months on medication 
for diabetes and/or 
hypertension 
• BP < 150/95 mmHg 
(<150/90 if diabetic) 
• HbA1c < 9% 
• Creatinine Clearance >50 
ml/min (or eGFR > 60) 
• CD4 > 100 
 
Criteria for Removal  • Defaulted 
• Viral load > 400 
• Pregnant 
• Symptoms meriting further 
assessment 
• Defaulted 
• Viral load > 400 
• Pregnant 
• Symptoms meriting further 
assessment 
• BP > 160/100 
• HbA1c > 10% 
• Step up in medication 
needed 
 









• Clinical (1) 
• Standard 
• Standard  
• Clinical (2) 
 
Staff present • Standard Visits - Counsellors 
• Blood and Clinical Visits – 
Professional Nurse 
• Standard Visits - Counsellors 
• Blood and Clinical Visits – 




With this pragmatic implementation has come some fragmentation, a lack of standardised 
guidance or model as well as unassessed outcomes.  There is therefore a basic need to 
evaluate these co-morbidity clubs not only to inform best practice at a local level but also to 
fill a wider research need.  Two key predictors of better health outcomes are adherence to 
medication and successful continuity of care and so the manuscript that follows looks at the 
important outcomes of viral load and retention data in these co-morbidity clubs [36].  As 
previously discussed, the viral load can help to predict not only adherence to ART but also 




There is a growing and complex population of individuals with both HIV and NCDs in low- 
and middle-income countries which is currently underserved in the health system.  There 
are compelling arguments for integrated care for this population from the perspective of the 
shared characteristics (for example the behaviour change needed for chronic disease 
management), the individual (in terms of adherence and acceptability) and the health 
system (in terms of resource- and system-effectiveness).  In many affected countries there is 
HIV system infrastructure in place and the HIV scale-up has been successful.  Because of 
this, there is increasing interest in harnessing this programme and its existing infrastructure 
to help address the needs of these co-morbid patients.   
 
One successful programme in South Africa has been the ART adherence club system and so 
this provides an ideal starting point for providing integrated care.  Co-morbidity clubs have 
been informally implemented in Cape Town, born out of a growing realisation of the unmet 
needs of this population, and so these clubs are well positioned to provide information on 
the effectiveness of integrated management of this population.  However, to date there has 
been no evaluation of patient outcomes from the co-morbidity clubs. The study that follows 
aims to address this research gap by comparing outcomes of HIV viral load and retention in 
the club model between those in HIV-only clubs and those in co-morbidity clubs.  These 
results are likely to not only inform local policy but to help address the need for analytical 
evidence on the outcomes of patients in integrated care and to thus inform NCD and HIV 
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Introduction:  Antiretroviral therapy (ART) adherence clubs have become an important 
model of care for those with Human Immunodeficiency Virus (HIV) who are stable on 
medication. With effective ART there is also a growing population of patients living with HIV 
as well as hypertension and/or diabetes and an urgent need for effective models of 
integrated care for this group. However, there is little evidence on differentiated models of 
care for HIV-positive patients with co-morbidities.  We compared patient outcomes in the 
recently implemented co-morbidity adherence club model and the established HIV-only 
adherence club model in Gugulethu, Cape Town. 
Methods:  Adults who were stable on ART and enrolled in an adherence club model (co-
morbidity or HIV-only) during 2016 were eligible for analysis. Using data from the routine 
club registers we assessed both retention in the club models and viral suppression (whilst in 
the club) from club enrolment through 12 months.  We compared these outcomes using 
Chi-squared tests and Fishers exact tests where appropriate, and outcome predictors were 
assessed using multivariable logistic regression models.  Kaplan-Meier estimates were also 
calculated to assess time to loss from club.  
Results:  Of 602 adults enrolled, 501 were from the HIV-only clubs and 101 from the co-
morbidity clubs.  Those enrolled into the co-morbidity clubs were significantly older and had 
been on anti-retroviral therapy (ART) for longer.  There was no difference in the proportion 
of those retained (84.2% vs 85.6%, p=0.703) or the proportion who were virally suppressed 
(97% vs 97%, p=0.999) in the co-morbidity club compared to the HIV-only club.  In 
multivariable models, adjusted for age, sex and duration on ART, there was no difference in 
retention (adjusted odds ratio [aOR] 0.75 95% confidence interval [CI] 0.38, 1.47) or viral 
suppression (aOR 0.98 95% CI 0.23, 4.14) by club model. 
Conclusion:  This novel study provides the first preliminary results for the integrated co-
morbidity club model, and shows comparable short-term patient outcomes between HIV-
only and co-morbidity clubs.  Although larger studies are needed, our findings provide 
reassurance that co-morbidity clubs can be implemented without affecting the outcomes of 




The introduction and scale-up of antiretroviral therapy (ART) has dramatically decreased 
mortality and increased life-expectancy of people living with HIV [1].  This program success 
has had the unanticipated consequence of generating a large population of people living 
with HIV who are, due to their increasing age as well as the direct effects of HIV and ART, at 
risk of developing non-communicable diseases (NCDs).  The incidence of NCDs, particularly 
hypertension and diabetes, is increasing disproportionately in low and middle-income 
countries [2].  South Africa, with its well-documented high burden of HIV, is thus 
experiencing the dual burdens of NCDs and HIV, two chronic conditions which are not 
without similarities and which are often experienced as comorbidities. 
 
The estimated prevalences of diabetes and hypertension in people living with HIV in low-
and-middle-income countries are high at 1.3-18% and 21.2% respectively [3].  There are 
powerful arguments for integrated care for this population [4].  Firstly, NCDs and HIV are 
both chronic conditions that tend to be progressive over time and thus effective treatments 
share an emphasis on self-management with community support and a need to monitor 
adherence and retention in health services [5].  Secondly, it is thought that these co-
morbidities have multiplicative damaging effects on health outcomes and thus present 
specific health-care needs [6].  Thirdly, those with co-morbidities have been shown to be at 
increased risk of poor adherence and the current patient burden of attending multiple 
appointments in vertical programmes puts extra strain on this [7–9].  Lastly, there is 
evidence that integrated management would be more cost-effective and efficient than 
multiple vertical programmes [10].  Health systems, in low- and middle- income countries 
especially, are already under-resourced and any increased efficiency in cost, time, resources 
and staff is much needed [11].   
 
Despite these calls, there is a striking lack of any large-scale integrated care models 
(particularly of an analytical nature) in low- and middle-income countries [9], with a 
corresponding dearth of evidence regarding optimal models of care for the comorbid 
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population [9, 12].   Existing descriptive and implementation-focused studies have provided 
an encouraging foundation for further research, with integrated chronic disease clinics in 
Ugandan and Cambodia demonstrating outcomes which were comparable to, or better 
than, African retention rates for those with HIV alone [13–15]. 
 
With the successful scale-up of the South African ART programme comes the potential to 
leverage the existing infrastructure to respond to the call for integrated co-morbidity care 
[16].   One method by which ART scale-up has been achieved is through the adherence club 
system, whereby PLHIV receive their antiretroviral mediation two-monthly in a non-clinic 
environment led by trained counsellors [17].  These clubs have demonstrated good 
retention and viral suppression outcomes in observational studies but currently exclude 
individuals with co-morbidities [18, 19].  This successful club model was adapted in Kenya in 
2013 to encompass those with NCDs and demonstrated a high club retention of 96.5% at 
one year [20].  Building on this, various facilities within Cape Town have informally 
implemented co-morbidity clubs into which those with HIV and hypertension and/or 
diabetes can enrol.  These initiatives have been pragmatic in nature with no standardised or 
recommended model and, to date, the outcomes of patients in the co-morbidity club model 
have not been evaluated. To address this gap, this retrospective cohort study compares the 
outcomes of both retention in the club model and HIV viral suppression between the newly-




A retrospective cohort study was conducted of patients who enrolled in the co-morbidity and 
HIV-only adherence club models at Gugulethu Community Health Centre (CHC), Cape Town 
during 2016.  Outcomes of club retention and HIV viral suppression for adults were compared 






Gugulethu has a population of approximately 100 000 and is predominantly of low-
socioeconomic status [22].   The Gugulethu CHC, which has a catchment area population of 
approximately 400 000, provides routine ART services in both clinic based and adherence 
club models. From January 2014 until December 2017, the number of adults retained in club 
care increased by 45% from 2420 to 3509, and by the end of 2017, 60% of the 5875 adults in 
ART services at Gugulethu CHC were being managed in the club system [23].  Co-morbidity 
clubs, for those with both HIV and hypertension and/or diabetes, were implemented in 
February 2016 following a perceived local need.   
 
ART Adherence Clubs 
 
The ART adherence clubs are well-established counsellor-run models whereby groups of 
around 30 patients meet five times a year to receive ART care. As of December 2017, 119 
HIV-only clubs were operating at Gugulethu CHC together with 7 co-morbidity clubs and 2 
adolescent clubs.  At the Gugulethu CHC, suitable patients (those who are stable and virally 
suppressed) are referred to the clubs from the ART clinic.  All clubs meet in a nearby off-site 
community hall and a full comparison of the HIV-only and co-morbidity club model structure 
and criteria is presented in Additional File 1. The details of the HIV-only club model have 
been described previously [24] but, briefly, a standard visit comprises health promotion, 
patient weight and symptom check as well as the dispensing of pre-packed ART. The 
additional checks performed for the blood and clinical visits are shown in Additional File 1.  
 
The newer co-morbidity clubs use the same inclusion criteria as the HIV-only clubs, but 
there are additional chronic disease indicator criteria including blood pressure, HbA1c and 
random glucose.  Following some incorrect enrolments in early 2016, a screening form with 
these criteria was implemented in April 2016.  Patients are removed from co-morbidity 
clubs as for the HIV-only clubs but also if their chronic disease indicators are above 
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prescribed thresholds.  Co-morbidity clubs are run by club counsellors with additional 
training in health promotion and lifestyle advice pertaining to diabetes and hypertension.  
The structure of visits is a little different, most obviously in that there are two scheduled 
annual clinical visits rather than one. 
  
As per the standard of care, the details of each club visit (HIV-only or co-morbidity) are 
entered into a paper register by the counsellors and these data are then captured 
electronically by a data clerk at the CHC.  For each club visit the retention status is recorded 
as one of the following: Current (the patient attended the club visit), DNA (the patient Did 
Not Attend the club visit or collect their medication within seven days of their scheduled 
visit), BTC (the patient was sent Back To Clinic care for further assessment), TFO (the patient 
requested a Transfer Out of the club), or RIP (the patient passed away).  For the co-




All adults who successfully enrolled (attended their first scheduled club appointment after 
referral from the CHC) into either the HIV-only or the co-morbidity clubs during 2016, and 
who had a routine HIV viral load scheduled after at least four months (121 days) in the club, 
were eligible for inclusion in this analysis.  Those who had no scheduled club clinical visit 
within the 12 months follow-up period were excluded (as per Figure 1).  Of note, there was 






For each enrolled adult, the primary outcomes of club retention status and viral suppression 
were assessed using routinely collected data through 12 months (plus a seven day grace 
period) post-enrolment in the club. 
   
Retention is an important outcome by which to judge the effectiveness and acceptability of 
any patient model of care.  Retention in the club was defined using the club status recorded 
at their last scheduled club visit whereby patients are considered retained if they attended 
the club visit within 7 days of the scheduled visit and had not been recorded as BTC or TFO. 
The date of loss of retention was defined as the first scheduled club date at which the 
patient’s club status was recorded as DNA, BTC, TFO or RIP.   
 
Viral suppression is a useful outcome by which to assess not only HIV control (particularly 
adherence to ART) but also control of NCDs by virtue of the association of adherence to ART 
with that to medication for NCDs [21, 25].  Viral suppression was defined as no viral load 
>400 copies/ml at a club clinical visit.  The date of loss of viral suppression was defined as 
the date of the first viral load >400 copies/ml taken during the follow-up period.   
 
Of note, there was no tracking of patients who were not retained in the club system and so 
these patients may or may not have continued their care outside of the club models.  All the 
patients were managed by Gugulethu CHC as per the usual standard of care over the study 








Patients entered the analysis at their first club visit and exited 12 months (plus a seven day 
window period) post-enrolment. 
   
Baseline characteristics, demographic and clinical, of enrolled adults were described overall 
and by club model using medians with interquartile ranges (IQR) and proportions.  
Comparisons of medians and proportions by club model were performed using Wilcoxon 
rank-sum and chi-squared tests respectively.  Whilst the cohort was assembled 
retrospectively, a cross-sectional analysis of retention by club model at 12 months post-
enrolment was conducted to determine both the proportion of patients in each model 
retained in the club system and the proportion of patients who were virally suppressed.  
These proportions were compared using chi-squared tests or Fishers exact tests as 
appropriate.  The median time spent in club was described by club model type and retention 
status.  In addition, Kaplan-Meier estimates of time to loss from club in both models are 
presented in supplementary material. 
 
Multivariable logistic regression models were fitted to examine the associations between 
baseline characteristics and outcomes of interest by club model and overall.  In a priori 
model design, the current literature was taken into account which describes lower viral 
suppression and higher loss of retention among young patients and males [18, 26].  It was 
also hypothesised that enrolment in the HIV-only and co-morbidity clubs may differ by age 
and sex. Because of this potential for confounding, the variables of age and sex were 
included in all models regardless of statistical significance.  The association of adherence 
with duration on ART is not clear-cut in the literature but because of an possible association 
with retention, duration was also included as a variable in all multivariable models [27].   
 
For those enrolled into the co-morbidity clubs, retention was also described by chronic 
disease (hypertension, diabetes or both).  All statistical tests were two-sided at alpha=0.05. 
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The study was powered at 90% for a 15% effect size.  Data were analysed using STATA 14.0 




This study obtained ethical approval from the University of Cape Town Human Research 
Ethics Committee.  Informed consent was not sought from individual patients as this study 
was a retrospective cohort analysis of routinely collected data, although the local standard 
of care involves all patients attending the ART clinic at Gugulethu CHC signing a simple 




A total of 602 patients were included in the analysis; 501 from the HIV-only club model and 
101 from the Co-morbidity club model. Figure 1 presents the participant selection for this 
analysis. 
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Figure 1.  Flow diagram of Eligibility Evaluation for those Enrolled into a Club in 2016 
 
 











Table 1 describes the baseline characteristics of the patients overall and by club model.  The 
median age at enrolment (38 years overall) differed significantly between the club models, 
being 36.5 years (IQR 30.5, 42.7) for the HIV-only clubs and 50.7 years (IQR 42.0, 56.0) for 
the co-morbidity clubs (p<0.001).  The overall female proportion was 70.3%, with no 
significant difference by club model.  The overall median duration on ART at enrolment was 
2.6 years (IQR 1.4, 5.7), this being significantly longer in the co-morbidity club (4.5 years 
[IQR 2.4, 8.3]) than the HIV-only clubs (2.3 years [IQR 1.3, 5.0]).  Of the 101 individuals 
enrolled into the co-morbidity clubs, 81 (80.2%) had hypertension, 7 (6.9%) diabetes and 8 
(7.9%) both. There were 5 patients (5.0%) who had neither hypertension nor diabetes due 
to incorrect enrolment into the clubs by clinic staff.   
 
  
858 scheduled for 1st 
club visit in 2016 
790 (92.1%) attended 
1st club visit in 2016 
511 (59.6%) had viral 
load scheduled >121 
days from first club 
visit 
501 (58.4%) had their 
1st clinical visit < 1 
year after their first 
club visit 
112 scheduled for 1st 
club visit in 2016 
102 (91.1%) attended 1st 
club visit in 2016 
101 (90.2%) had viral 
load scheduled >121 
days from their first club 
visit 
101 (90.2%) had their 
1st clinical visit < 1 year 
after their first club visit 
 
Co-Morbidity Club                                HIV-only Club                                
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Table 1.  Demographic and Clinical Characteristics of those Enrolled into Club in 2016, 
Overall and by Club Model 
 
Variable (at club 
enrolment) 





602 501 (83.2) 101 (16.8) - 
Median (IQR) 








Female, n (%) 423 (70.3) 353 (70.5) 70 (69.3) 0.817 
Median (IQR) 
years on ART 
 
2.6 (1.4, 5.7) 
 
2.3 (1.3, 5.0) 
 




Table 2 presents retention and viral suppression overall and by club model. At 12 months 
post-enrolment, the overall retention in club care was 85.4%.   The retention in the HIV-only 
clubs was 85.6% and that in the co-morbidity clubs was 84.2% with no statistically significant 
difference between these proportions (p = 0.703).  Of note, survival analysis also showed no 
statistically significant difference by club model in the proportion retained over time 
(p=0.340).  The Kaplan-Meier estimates are presented in Additional File 2.  The proportion 
of patients who were virally suppressed was 97.0% overall as well as in both club models.  
Eight patients from the co-morbidity clubs (7.9%) and 36 patients from the HIV-only clubs 
(7.2%) had no club viral load result and were included as virally suppressed but results did 
not change substantially in sensitivity analyses assuming missing viral loads were not virally 
suppressed (data not shown).  The median time in the club model at the viral load blood test 
differed significantly between club models, being 5.5 months for the HIV-only clubs and 3.7 
months for the co-morbidity clubs (p<0.001).  Among those who were not retained in club 
at 12 months, the median time in club appeared similar between club models.  The reasons 
for loss of retention differed significantly by club model (p=0.004).  The commonest reason 
for loss of retention from the HIV-only clubs was failure to attend (DNA) whereas for the co-
morbidity clubs it was being sent back to clinic (BTC).  The reasons for being BTC also 
differed between club models, with a high viral load being the commonest cause for HIV-
only clubs (70.6%) and high blood pressure for the co-morbidity clubs (54.5%).   The small 
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sample size precluded further statistical analysis.  Further information regarding reasons for 
being sent back to clinic, by club model, is presented in Additional File 3. 
 
Table 2.  Retention in Club and Viral Rebound by 12 months Post-enrolment in HIV-only and 
Co-morbidity clubs.  All cells are presented as n (%) unless specified otherwise 
 
Outcome Overall HIV-only Club Co-morbidity 
Club 
p-value 
Retention 514 (85.4) 429 (85.6) 85 (84.2) 0.703 
Not retained  88 (14.6) 72 (14.4) 16 (15.8)  
Did Not Attend 













months in club 
if not retained 
5.5 (5.5, 7.4) 5.5 (5.5, 7.4) 5.5 (3.7, 6.4) 0.050 
Viral 
suppression 
584 (97.0) 486 (97.0) ‡ 98 (97.0)† 0.999 
Median (IQR) 
months in club 
at time of viral 
load measure 
5.5 (3.7, 5.5) 5.5 (3.7, 5.5) 3.7 (3.7, 3.7) P<0.001 
†8 (7.9%) viral load results missing, ‡ 36 (7.2%) viral load results missing 
 
In both univariable and multivariable logistic regression models there were no statistically 
significant predictors of retention in club or viral suppression in this cohort (Table 3).   In the 
multivariable model, adjusted for age, sex and increasing duration on ART, there was a 25% 
decreased odds of retention for those in the co-morbidity clubs compared to those in the 
HIV-only clubs (aOR 0.75 (0.38, 1.47)).  There was a very small decreased odds of viral 
suppression in the co-morbidity clubs compared to the HIV-only clubs (aOR 0.98 (0.24, 
4.14)).   Age at enrolment did not seem to be associated with retention or viral suppression 
in either club model.  Increasing duration on ART didn’t appear associated with either HIV-
only or co-morbidity club retention but appeared to have a positive effect on viral 
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suppression overall (aOR 1.20 (0.97, 1.47)) and in both club models.  The effect of sex on 
retention and viral suppression appeared to differ by club model, with females being more 
likely to be retained than males in both club models.  Sensitivity analyses were performed 
for the overall primary outcomes with and without the five individuals in the co-morbidity 
club model who were incorrectly enrolled and no differences in outcomes were found (data 




Table 3.  Crude and Adjusted Logistic Regression Results predicting Retention in Club and 
Viral Suppression Overall and by Club Model. Results expressed as odds ratios (OR) with 95% 
confidence intervals 
 
 Overall  HIV-only Clubs Co-morbidity Clubs 
 Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted 


















































    


















































    
† All patients classified as virally suppressed if no recorded viral load>400 copies/ml 
 
Primary outcomes for those in the co-morbidity clubs, described by chronic illness, are 
shown in Table 4. The numbers of patients with diabetes or both hypertension and diabetes 
were very small but retention and viral suppression proportions did not appear to differ 
between the different categories of comorbid illness.  Only three participants in the co-
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morbidity club experienced a viral load >400 copies/ml and all three had hypertension 
alone.   
 
 
Table 4.  Retention and Viral Suppression in the Co-morbidity Club Model recorded by 
Illness. All cells are n (%) 
 
 Hypertension Diabetes Both Neither 
Total  81 (80.2) 7 (6.9) 8 (7.9) 5 (5) 
Retention 67 (82.7) 6 (85.7) 7 (87.5) 5 (100.0) 
  Did Not Attend 4 (4.9) 0 (0) 0 (0) 0 (0) 
Back To Clinic 9 (11.1) 1 (14.3) 1 (12.5) 0 (0) 
Transfer Out 1 (1.2) 0 (0) 0 (0) 0 (0) 





This analysis provides preliminary insights into important outcomes for HIV-positive patients 
in a co-morbidity club model, comparing them to patients in the well-described HIV-only 
club model at 12 months post-enrolment. In this first analysis of a co-morbidity club model 
in this setting, we found no differences in 12 month retention in club or viral suppression 
between the two club models.  
 
Compared to the HIV-only club model, we found that those who enrolled into the co-
morbidity club tended to be older and to have been on ART for longer. This is an expected 
finding due to the increased prevalence of co-morbidities with age and duration on ART as 
well as the delay in implementing co-morbidity clubs.  Once enrolled, those in the co-
morbidity club were more likely to be BTC but less likely to be DNA than those in the HIV-
only club. BTC from the co-morbidity club was predominantly NCD-related (mostly for high 
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blood pressure) and likely reflects the increased frequency of clinical monitoring, 
particularly that of blood pressure.  The fewer DNAs likely reflect a satisfaction with the co-
morbidity club model of care but may also reflect an element of reduced stigma associated 
with attending a co-morbidity club compared to an HIV-only club.  
 
Although no statistically significant differences in retention in club were found, multivariable 
models from this analysis suggest that there is a tendency towards poorer retention among 
the co-morbid group.  Of note, there was a negligible difference in odds of viral suppression 
between club models. This points to comparable control of HIV in both models and supports 
the finding that the reasons for loss of retention in the co-morbidity club were mostly NCD-
related. 
 
Our findings in the HIV-only club model are comparable to those in the literature with a 
recent study on HIV-only clubs finding a club retention of 77.6% and a viral suppression 
proportion of 95.7% at 16 months [18].  The demographics of those enrolled into the HIV-
only club were similar to those in other club literature in terms of sex and age. The duration 
on ART was, however, shorter in this study than other club literature, probably owing to the 
fact that the club model is now an established standard of care in this setting [19].   
Although there are few available studies on co-morbidity models of care, the retention 
proportions in this study compare favourably to mixed chronic disease clinics such as those 
in Cambodia and Uganda [14, 28].  The Kenyan MACs also found high retention rates at 1 
year of 96.5% but their definition of retention included all those still in in either club or 
clinic-based care and very few of the patients had co-existing HIV and NCDs [20].  
 
In this study, age was not associated with retention or viral suppression in either club 
model.  This is not in keeping with the majority of the literature, but may be explained by 
the fact that comparable studies involved larger ranges of ages and more adolescents [18, 
29].  Increasing duration on ART increased the odds of viral suppression overall and in each 
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club model. This is notable as other studies on HIV-only clubs have found a decreased viral 
suppression with increased time on ART [18, 19].   
 
The following limitations must also be considered.  Firstly, these results come from a newly-
implemented project and the sample size was reasonably small. Even though the model 
associations were not statistically significant, the wide confidence intervals around some 
reasonably large effect sizes point to a lack of power and we cannot preclude the existence 
of an association.  For this reason, the non-significantly reduced odds of retention in a co-
morbidity club compared to a HIV-only club needs further evaluation with a larger sample 
size and ideally a longer follow-up period.  Secondly, the median time in the club model at 
the viral load blood test was significantly higher for the HIV-only clubs compared to the co-
morbidity clubs.  This was due to the new implementation of the co-morbidity clubs 
meaning that all patients entered these clubs at the first standard visit (see Additional File 
1).  It was therefore possible that those in the HIV-only clubs had more time in which to lose 
viral suppression.  Thirdly, all missing viral loads were classed as virally suppressed in the 
analyses leading to a possible underestimation of viral suppression, although sensitivity 
analyses did not significantly change the results.  Future analyses of larger cohorts may 
warrant a competing risks approach, or consideration of retention as a confounder for viral 
suppression.  Fourthly, no potential clustering effect by club membership within each club 
model was accounted for.  Lastly, whilst the control group is appropriate and allows 
meaningful comparison, potential alternative control groups would be those patients with 
both HIV and NCDs who are being managed in clinics (thereby assessing the direct impact of 
the club system for this population) and those patients who have NCDs alone and are being 




This study, to our knowledge, is the first to directly compare club clinical outcomes between 
adults with HIV alone and those with HIV and hypertension and/or diabetes.  These findings 
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provide early evidence of comparable outcomes for the co-morbidity and HIV-only club 
models and provide reassurance that co-morbidity clubs can be implemented without 
affecting the outcomes of HIV care.   
 
Although further evidence on larger cohorts with longer follow-up are required, as well as 
further investigation regarding the differential reasons for loss of retention by club model, 
these findings provide reassurance that the under-served population with HIV and co-
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Additional File 1:  Comparison of Club Models 
AREAS OF CARE CLUB MODEL 
 HIV-ONLY CLUB CO-MORBIDITY CLUB 
Eligibility 
 
• ≥6 months on ARVs 
• Viral load < 400 copies/ml 
• No other co-morbidities 
• CD4 > 100 
• Not pregnant 
• ≥6 months on ARVs 
• Viral load < 400 copies/ml 
• ≥6 months on medication for diabetes 
and/or hypertension 
• CD4 > 100 
• Not pregnant 
• BP (mmHg) less than target 
o 150/95 for hypertension  
o 150/90 for diabetes 
• HbA1c < 9% for diabetes 
• Creatinine Clearance >50 ml/min (or 
eGFR > 60)  
Criteria for 
Removal  
• Did Not Attend 
• Viral load > 400 copies/ml 
• Pregnant 
• Symptoms meriting further 
assessment 
• Did Not Attend 
• Viral load > 400 copies/ml 
• Pregnant 
• Symptoms meriting further assessment 
• BP > 160/100 for all  
• HbA1c > 10% for diabetes 





• Blood (viral load, safety bloods) 







o  Viral load, safety bloods, 
creatinine, cholesterol if previous 
cholesterol > 5 mmol/l for all 
o HbA1c for diabetes 
• Clinical 1  
o Blood results, random glucose, BP 
for all 
• Standard 
• Standard  
• Clinical 2  
o BP for all 
o Foot screen, random glucose, urine, 
date for retinal screening for 
diabetes 
Staff present • Standard Visits – Counsellors 
• Blood and Clinical Visits – 
Professional Nurse 
• Standard Visits - Counsellors 
• Blood and Clinical Visits – Clinical Nurse 
Practitioner 
eGFR: Estimated glomerular filtration rate; BP: Blood Pressure 
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Additional File 2:  Survival Analysis 
A survival analysis was performed for all those enrolled into the club model (either HIV-only 
or co-morbidity) during 2016.  The analysis end date was the 1st December 2017, the date of 
the last scheduled club visit for 2017 plus 7 days grace period.  The outcome (“event”) was 
loss of retention in the club (defined as a status of DNA, BTC, TFO or RIP) and the survival 
time was the time from club enrolment until a recorded loss of retention or until the 1st 
December 2017 depending on which came first.   
The sample size of 601 individuals contributed 9493.2 person months and 119 lost retention 
in club.  One individual in the co-morbidity club model requested transfer out at the first 
scheduled appointment so was not included in the survival analysis.  The Kaplan-Meier 
survival curves are shown in Figure 1.   
Figure 1.  Kaplan-Meier estimates of the proportion of patients who did not reach the 
primary outcome of loss of retention in the HIV-only and Co-morbidity club model 
 
 
Figure 1 shows a reduction in proportion retained over time in the Co-morbidity club 
compared to the HIV-only club but a log-rank test for equality of survivor functions showed 
this difference to be non-statistically significant (p=0.340).  Although the lines show 
increased divergence after around 20 months, this is likely to be due to the small numbers 
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Reasons for being sent back to clinic by club model
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Part D: Appendices 
Appendix A. Screening Form for Co-Morbidity Clubs 
Date:      /    / 2 0    
 
Patient Name:     _____________________________________________________________ 
 
Patient Folder Number:    ________________ 
 
 
Has the patient been on ARVs for >6 months? 
 
Yes    No  
Is the latest viral load <400? 
 
Yes    No  
Is the CD4 >100? 
 
Yes    No  
Does the patient have either diabetes, hypertension or both? 
 
Yes    No  
Does the patient have any other chronic diseases that require 
regular clinical review? 
 
Yes    No  
Is the BP (within 6 months) < 150/95? 
 
Yes    No  
If diabetic, is the BP (within the last 6 months) < 150/90? 
 
Yes    No  
If diabetic, is the HbA1c (within 1 year) < 9%? 
 
Yes    No  
Is the eGFR>60 or the Creatinine clearance >50 (within the last 6 
months) 
 
Yes    No  
Has the patient been on their chronic disease (diabetes or 
hypertension) medication for > 6months? 
 
Yes    No  
 
 
If all white boxes ticked – ELIGIBLE for Chronic Club 
If any grey boxes ticked – INELIGIBLE for Chronic Club  
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Appendix D. JIAS Author Guidelines 
 
Research - full reports of data from original research studies 
 
Headings: Introduction, Methods, Results, Conclusions 
Word limit: 350 words 
 
Main text: 
Headings: Introduction, Methods, Results, Discussion, Conclusions 
Word limit: 3500 words 
Numbers of figures and tables: Unlimited 
Additional files: Yes 
 
Main Text File 
The text file should be presented in the following order: 
 
1. Title page 
2. Keywords 
3. Abstract 
4. Main text 










The title should not contain abbreviations, except commonly used abbreviations such as HIV 
or AIDS (see Wiley's best practice SEO tips). 
 
On the title page, you should mention the title of the manuscript, list all authors' names in 
full, and list any study groups if applicable. Each authors' affiliation should be numbered in 
superscript consecutively and listed underneath, including department, institution, city and 
country. 
 
The corresponding author should be marked with the symbol § in superscript and full 
contact details should be provided, including a telephone number with country code. 
Authors who have contributed equally to the work should be marked with the symbol * in 
superscript. Deceased authors should be marked with the symbol ^ in superscript. The email 
addresses of all authors should be listed by their initials. 
 
Keywords 
Pease provide six keywords. Keywords should be taken from those recommended by the US 
National Library of Medicine's Medical Subject Headings (MeSH) browser list at 
https://www.nlm.nih.gov/mesh/. Preferably alternate words to those found in the abstract 
in order to improve search hits for the article in repositories. 
 
Abstract 
The Abstract should not exceed 350 words and should be structured according to the 
headings of the selected article category (see above), excluding the heading “Discussion” for 
Research articles. Avoid using abbreviations and do not cite references in the Abstract. If 
you are reporting results from a controlled health care intervention, please include your trial 
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registry, together with your unique identifying number at the end of the Abstract. For 






The Introduction section should introduce the topic to readers without specialist knowledge 
in that area and must clearly outline the current state of knowledge in this field, the 
motivation and the aim of the study or the article. 
 
Methods 
The Methods section should include all information necessary to repeat the study, in 
particular, the study design, how data was collected and analyzed, clarifying the choice of 
methods that were made. If applicable, you should describe the setting of the study, the 
dates the study were conducted, and the sample or participants, as well as necessary power 
calculations and materials, including statistical packages, used. Interventions and 
programmes should be described in detail. Generic names for drugs or any molecules should 
be used. 
 
All studies involving humans or animals require a statement on ethical approval, and for the 
former, the consent procedure that was followed. Please include the names of the ethics 
review board(s) that approved the study. If the research study was specific to one 





This section should include only data and findings from the authors' study. Presentation of 
statistical results should mention confidence intervals and levels of significance where 
appropriate. Quotes from qualitative study participants of less than three lines should be 
quoted in the text using quotation marks. For quotes longer than three lines, place the 
quote in a separate, indented paragraph and introduce it with a colon. No quotation marks 
are needed in this case. Details of the participant can be added in round brackets following 
the quote, but should not contain identifiable information to ensure confidentiality. 
Clarifications within the quotation should be placed in square brackets. 
 
Submitting authors are strongly encouraged to include data disaggregated by sex (and, 
whenever possible, by race) and provide a comprehensive analysis of gender and racial 
differences. The authors should include the number and percentage of men, women and, if 
appropriate, transgender persons who participated in the research study. Anatomical and 
physiological differences between men and women (height, weight, body fat-to-muscle 
ratios, cell counts, hormonal cycles, etc.), as well as social and cultural variables (socio-
economic, education, access to care, etc.), should be taken into consideration in the 
presentation of data and/or analysis of the results. 
 
Discussion 
In the Discussion section, you should discuss your main findings and place these within the 
context of the current body of knowledge in the field. Limitations of the study, for example, 
selection bias, can also be discussed, and should address how these influence the results 
and conclusions. If statistically significant differences were found between men and women 
or between different racial or cultural groups in the effects of the studied intervention, the 
implications, if any, for clinical and/or public health should be adequately discussed. 
 
Conclusions 
In your Conclusions section, state your key messages from the study and explain their 
importance and relevance, as well as implications. Future studies and recommendations can 
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be included in this section. The conclusions drawn must be strictly based on the data 
provided. 
 
Conflict of Interest Statement 
Authors will be asked to provide a conflict of interest statement during the submission 
process. For details on what to include in this section, see the ‘Conflict of Interest’ section in 
the Editorial Policies and Ethical Considerations section below. Submitting authors should 
ensure they liaise with all co-authors to confirm agreement with the final statement. 
 
Authorship 
Please refer to the journal’s Authorship policy in the Editorial Policies and Ethical 
Considerations section for details on author listing eligibility. The individual contributions of 
each author must be specified in the Authors' Contributions section. Please use authors' 
initials and state that all authors have read and approved the final manuscript. An example 
of a suitable statement is: “S.W., N.J., D.W. and S.S. performed the research. S.W., N.J., H.H. 
and T.L. designed the research study. H.H. and S.S. contributed essential reagents or tools. 
S.W., N.J. and D.W. analysed the data. S.W. and N.J. wrote the paper.” Please see the 
‘Authorship’ section in the Editorial Policies and Ethical Considerations section below for 
what constitutes authorship. 
 
Acknowledgments 
Contributions from anyone who does not meet the criteria for authorship should be listed, 
with permission from the contributor, in an Acknowledgments section. Financial and 






All external sources of information should be referenced within the text, the tables and 
figures, using consecutive numbering in square brackets, e.g. [1], [3-5], [3,4]. The references 
should be up to date and adequately reflect the current state of knowledge in the field. 
Citation bias, for example, by country or point of view must be avoided. Numbers of 
references are unlimited for all article categories and should be formatted in standard 
Vancouver style; see Sample references from ICMJE . Unpublished observations, personal 
communications and manuscripts currently under consideration should be cited in the text 
in round brackets and not in the reference list. 
 
Tables 
They should be supplied as editable files, not pasted as images. Tables should be inserted 
into the text. They should have the header: "Table 1. Title of table". All tables should be 
cited in the text in consecutive order. The tables should not contain colour or shading, and 
no vertical, visible lines. If tables are copied or adapted from another source, permission 
must be sought by the authors prior to publication and these should be clearly cited as such. 
If a table spans more than one page, authors may want to consider uploading the table as 
an additional file instead. Tables should be self-contained and complement, not duplicate, 
information contained in the text. A legend can be provided underneath the title, listing any 
abbreviations or meanings of symbols used. If several tables are included, please ensure 
that symbols are used consistently. Legends should be concise but comprehensive – the 
table, legend, and footnotes must be understandable without reference to the text. All 
abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in 
that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or 
SEM should be identified in the headings. 
 
Figures 
Figures should be cropped as closely as possible and have the header: "Figure 1. Title of 




Although authors are encouraged to send the highest-quality figures possible, for peer-
review purposes, a wide variety of formats, sizes, and resolutions are accepted. Click here 
for the basic figure requirements for figures submitted with manuscripts for initial peer 
review, as well as the more detailed post-acceptance figure requirements. 
 
Figure legends should be concise but comprehensive – the figure and its legend must be 
understandable without reference to the text. Include definitions of any symbols used and 
define/explain all abbreviations and units of measurement. If several figures are included, 





Appendices will be published after the references. For submission, they should be supplied 
as separate files but referred to in the text. 
 
Supporting Information 
Supporting information is information that is not essential to the article, but provides 
greater depth and background. It is hosted online and appears without editing or 
typesetting. It may include tables, figures, videos, datasets, etc. Click here for Wiley’s FAQs 
on supporting information. 
 
Note: If data, scripts, or other artefacts used to generate the analyses presented in the 
paper are available via a publicly available data repository, authors should include a 




General Style Points 
The following points provide general advice on formatting and style: 
 
• Abbreviations: In general, terms should not be abbreviated unless they are used 
repeatedly and the abbreviation is helpful to the reader. Initially, use the word in full, 
followed by the abbreviation in parentheses. Thereafter use the abbreviation only. 
• Acronyms: Acronyms should be used sparingly, and not in headings or in the Abstract. 
Only commonly known acronyms may be used, and they should be spelt out at first use 
followed by the abbreviation in brackets. SI units should be used, with litre and molar being 
permitted. 
• Units of measurement: Measurements should be given in SI or SI-derived units. Visit the 
Bureau International des Poids et Mesures (BIPM) website here for more information about 
SI units. 
• Numbers: Numbers under 10 are spelt out, except for: measurements with a unit 
(8mmol/l); age (6 weeks old), or lists with other numbers (11 dogs, 9 cats, 4 gerbils). 
• Trade Names: Chemical substances should be referred to by the generic name only. Trade 
names should not be used. Drugs should be referred to by their generic names. If 
proprietary drugs have been used in the study, refer to these by their generic name, 
mentioning the proprietary name and the name and location of the manufacturer in 
parentheses. 
• Footnotes: Footnotes are not allowed in the text, the information shall be included 
directly into the text, where it fits best, and if these are references, to include in the 
reference section at the end. 
• Language: All submissions must be in UK English (International) and UN-accepted 
terminology should be followed. No capitalization should be used except for grammatically 
correct use, official names and titles, and abbreviations. 
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• General recommendation: Use line spacing of 1.5 and an easily readable font, for example, 
Times New Roman, size 12. Your manuscript should contain line numbers to facilitate 
editors' and reviewers' comments 
 
